



**Angel E. Alsina, M.D., FACS, FAASLD**  
**ABSTRACTS**

50  $\mu$ m

**Abstracts - National**

1. Preliminary Experience with Low Dose OKT3 in Renal and Liver Transplant Recipients. Schweizer R, Roper L, **Alsina A**, Hull D, and Bartus S. American College of Transplant Physicians Tenth Annual Meeting, May 1991, Chicago, IL.
2. Causes of Late Graft Failure in Cadaveric Kidney Transplant Recipients. Bergman L, **Alsina A**, Roper L, Bartus S, Hull D, and Schweizer R. Transplant Fellows Symposium, November 1991, Chicago, IL.
3. Auxiliary Partial Liver Transplantation in Pigs with Acute Ischemic Liver Failure. Nagashima I, Bergman L, **Alsina A**, and Schweizer R. Liver Transplantation Symposium, 1992, Minneapolis, MN.
4. Decreased Cellular Immune Response in Hepatitis C Patients Awaiting Liver Transplantation. Huang J, Lopez-Cepero M, Mayes J, **Alsina A**. American Society of Transplantation 2004.
5. Correlation of Cell Mediated Immune Response with Liver Allograft biopsy in Liver Transplant Recipients with Hepatitis C. Huang, J, Lopez-Cepero M, Mayes J, **Alsina A**. American Society of Transplantation 2004.
6. Prophylactic Biliary Stent Placement after Orthotopic Liver Transplantation to Prevent Biliary Complications. Popli, R; Brady, P; **Alsina A**; Florida Gastroenterology Society October 2002.
7. Predictive Factors of Successful Liver Transplantation in a Population with Limited Access. Gregory, F, Vazquez M, Lozano H, Guzman A, **Alsina A**. Digestive Disease Week 2004.
8. Analysis of the First 100 Liver Transplant Recipients from the Commonwealth of Puerto Rico: The LifeLink Healthcare Institute-University of Puerto Rico Experience. **Alsina A**; Torres E; et al. DDW May 2006, Los Angeles, CA.
9. Single Center Comparative Study of the Efficacy of Valgancyclovir Vs Gancyclovir in High Risk CMV Mismatched Liver Transplantation. **Alsina A**, Bowers VD, Bruce D, Huang J, Leone JP, Nguyen T, Mendoza A, Silverman D. ASTS Winter Symposium, Marco Island, FL 2008.
10. Utility in Liver Transplantation for Fulminant Hepatic Failure: The Non organ for the Non eligible Liver Transplant recipient. **Alsina A**, Bowers V, Nguyen T, Leone J, Huang J, Ikram M, Kendall W. ASTS Winter Symposium, Marco Island, FL, 2009.
11. Liver Transplantation for hepatocellular carcinoma in well compensated cirrhotics. **Alsina A**, et al. AASLD 2010, Poster Presentation.
12. Barriers to Liver Transplant in Puerto Ricans With Chronic Liver Disease. Rivera, MN, Jowsey S, **Alsina A**, Torres EA. 12<sup>th</sup> International Symposium on health Disparities, Nashville, TN 2010.

13. Outcome after TIPS: A Bridge to Nowhere. Toomey P, Golkar F, Hernandez J, Clark W, Luberic K, **Alsina A**, Rosemurgy A AHPBA Annual Meeting, 2011 Miami Beach, FL.
14. Uncovering the Truth about Covered Stents: Is There a Difference Between Covered vs. Uncovered Stents with TIPS? Golkar F, Luberic K, Toomey P, Okpaleke M, Vice M, Hernandez J, Clark W, Ross J, **Alsina A**, Rosemurgy A. Association of VA Surgeons 35th Annual Meeting - April 2011, Irvine, California.
15. Hepatic function in a liver transplant candidate with hepatocellular carcinoma: Impact on cancer recurrence and outcomes. **Alsina A**, Rojas H, Franco E, McGhee B, Leone J, Bowers V, Huang J, Mendoza A, Kemmer N, Osman-Mohamed H, Neff G. AASLD 2011.
16. Impact of Drug Eluting Bead Chemoembolization on Survival and Recurrence of Hepatocellular Carcinoma (HCC) Post Liver Transplantation. Rojas H, Franco E, Davis C, Zweibel B, Brantley S, Neff G, **Alsina A**. AASLD 2011.
17. Assessment of Tumor Necrosis Following Chemoembolization for Hepatocellular Carcinoma in Liver Transplantation: Possible Benefit of Drug-eluting Beads, **Alsina A**, et al. ATC 2011.
18. Collateral Damage of Liver Transplantation in the Well Compensated Cirrhotic with Hepatocellular Carcinoma. **Alsina A**, Franco E, Leone J, Osman-Mohamed H, Huang J, Bowers V, Rojas H, McGhee B, Mendoza A, Kemmer N, Neff G. AASLD 2011.
19. Evaluation of Liver Transplantation Outcomes in Chronic Hepatitis C Genotype 1b versus 1a. Tong A, Silverman A, Franco E, Neff G, **Alsina A**. AASLD 2011.
20. **Alsina A**, Makris A. Differences in Hepatocellular Carcinoma Rates in Florida. American Statistical Association, Orlando, FL 2012
21. **Alsina A**, Makris A, et al. Epidemiology of Hepatocellular Carcinoma in Florida. High Incidence Near Liver Transplant Centers. ASTS Winter Symposium, Miami, FL 2012
22. Mathur A, Leone J, Franco E, Osman-Mohamed H, Rojas H, Kemmer N, Neff G, Rosemurgy A, **Alsina A**. Obesity Portends an Increased Morbidity, Abbreviated Survival and Early Recurrence Following OLT for Hepatocellular Carcinoma AHPBA, Miami, FL 2012
23. Outcomes in patients with small hepatocellular carcinoma and chronic hepatitis C infection treated with RFA and antiviral therapy. Kemmer N, **Alsina A**, et al. AASLD 2012
24. Serum Albumin and Resource Utilization in Liver Transplantation, Kemmer N, **Alsina A**, et al. 2012 AASLD
25. Post liver transplant safety of rapid immunosuppression conversion prior to Daa/Peg/Riba therapy for recurrent HCV, Kemmer N, **Alsina A**, et al. 2012 AASLD
26. Outcomes in patients with cirrhosis using direct antiviral agents, ribavirin and pegylated interferon Kemmer N, **Alsina A**, et al. 2012 AASLD
27. Patient's Distance from a Liver Transplant Center Affects Outcomes Post Transplantation: Impact of Hepatitis C. **Alsina A**, Makris A, et al. AASLD 2012
28. Hepatic encephalopathy, physical functioning, and associated complications with compensated cirrhosis. Neff G, Kemmer N, Christian M, Ramirez M, Parkinson E, Cece, E, Cooper J, Mendoza A, **Alsina A**. ACG 2012 Annual Meeting.

29. Outcomes in length of Hospital stay in Cirrhotics admitted for Overt Hepatic Encephalopathy. Neff G, Kemmer N, Parkinson E, Cece E, Christian M, Webster H, Cooper J, Houston S, Mendoza A, Gardner J, A, **Alsina A**, Bowers V. ACG 2012 Annual Meeting.
30. Readmission Rates and Maintenance of Overt Hepatic Encephalopathy. Neff G, Kemmer N, Cece E, Parkinson E, Christian M, Palamittam D, Cooper J, Mendoza A, **Alsina A**. ACG 2012 Annual Meeting.
31. Long Term Survival Following Overt Hepatic Encephalopathy. Neff G, Christian M, Ramirez M, Webster H, Galambo F, Parkinson E, Cece E, Cooper J, **Alsina A**, Mendoza A, Kemmer N. ACG 2012 Annual Meeting.
32. Malnutrition in Cirrhotics; Daily Calorie Counts and Nutritional Deficits Uncovered. Neff G, Kemmer N, Parkinson E, Cece E, Christian M, Galambo F, Cooper J, Mendoza A, **Alsina A**. ACG 2012 Annual Meeting.
33. Impact of Hispanic Ethnicity on Tacrolimus Dosing in Liver Transplant Patients. Silverman D, **Alsina A**, et al. American College of Pharmacy Annual Meeting 2013
34. Longer Distance to Liver Transplant Center Increases Mortality. Makris A, Zheng J, **Alsina A**, Huffer F, Devidas M. 2013 Graduate Student and Postdoctoral Scholar Research Symposium, University of South Florida. March 2013.
35. Longer Distance to Liver Transplant Center Increases Mortality. Makris A, Zheng J, **Alsina A**, Huffer F, Devidas 2013 USF Research Day
36. Survival and cancer recurrence in liver transplantation for hepatocellular carcinoma in the last decade. Is there progress? **Alsina A**, et al. AHPBA 2013
37. Improved Survival with Sorafenib and Multimodality Therapy in Recurrent Hepatocellular Carcinoma Following Liver Transplantation: A Preliminary Report. **Alsina A**, et al. ASTS Winter 2013
38. Safety of Rapid immunosuppression Conversion Prior to Direct Antiviral Agents for Recurrent Hepatitis C Following Liver Transplantation. **Alsina A**, et al. ASTS Winter 2013
39. Predictors of outcomes in liver transplantation for hepatocellular carcinoma in the MELD era. **Alsina A**, et al. ASTS Winter 2013
40. Smoothing the likelihood function of distance effect in liver transplantation. **Alsina A**, Makris A, et al. AASLD 2013
41. High utilization of liver transplantation for hepatocellular carcinoma. Is it concerning? **Alsina A**, et al. AHPBA 2014.
42. Can sorafenib extends survival of recurrent hepatocellular carcinoma following liver transplantation. **Alsina A**, et al. Southeaster Surgical Congress, 2014.
43. A Socioeconomic Predictive Model for Access and Survival of Liver Transplant Patients: The Effects of Distance, Race, Insurance, Income, Work Status and Education. R Jacob, M Katzen, A Makris, **A Alsina**. USF Research Day 2014. Outstanding Undergraduate Poster
44. High utilization of liver transplantation for hepatocellular carcinoma. Is it concerning? K Vu, J Arrobas, E Franco, N Kemmer, A Valencia, A Makris, **A Alsina**. USF Research Day 2014.

45. Deleterious effect of body mass index and prior abdominal surgery on liver transplant complications. **Alsina A**, Zheng J, Makris A, Shim J, Franco S, Albers C, Kemmer N. AASLD 2014.
46. Is There a Roll for Prophylactic Internal Biliary Stents With Orthotopic Liver Transplants to prevent Biliary Complications After Liver Transplant? Lipka S, Rodriguez A, Shiani A, Sethi S, Nehaul M, Snyder M, Chirumamilla, Valenzuela M, Lai A, Kumar A, Kemmer N, Brady P, and **Alsina A**. ACG 2015.
47. Vascular complications after trans-arterial chemoembolization in orthotopic liver transplant patients. Shiani A, Lipka S, Lai A, Sethi S, Nehaul R, Chirumamilla S, Snyder M, Strauss A, Valenzuela M, Rodriguez A, Kumar A, **Alsina A**, Kemmer N, Brady P. ACG 2015
48. The impact of hepatitis C virus on biliary and vascular complications post-orthotopic liver transplantation. Rodriguez A, Shiani A, Lipka S, Sethi S, Nehaul R, Chirumamilla S, Snyder M, Strauss A, Valenzuela M, Lai A, Lalama M, Kumar A, **Alsina A**, Kemmer N, Pinkas H, Brady P. ACG 2015
49. The incidence of biliary strictures after trans-arterial chemoembolization for hepatocellular carcinoma in orthotopic liver transplant patients. Shiani A, Rodriguez A, Lipka S, Sethi S, Nehaul R, Chirumamilla S, Snyder M, Strauss A, Valenzuela M, Lai A, A, Kumar A, **Alsina A**, Kemmer N, Brady P. ACG 2015
50. Successful liver transplantation for hyperammonemic fibrolamellar hepatocellular carcinoma: A case report. Nakshabandi A, Franco E, Kemmer N, **Alsina A**. ACG 2015.
51. Tracking long term survival in hepatocellular carcinoma by a liver cancer multi-disciplinary team: The ultimate team. **Alsina A**, Makris A, Valencia A, Allison J, Claudio R, Johnstone M, Shim J, Franco E, Albers C, Kemmer N, Davis C, Zweibel B. ASTS 2015
52. A pilot study of high-risk adjuvant sorafenib in high risk liver transplantation for hepatocellular carcinoma. **Alsina A**, Franco E, Makris A, Shim J, Allison R, Claudio R, Johnstone M, Barber K, Albers C, Kemmer N. AHPBA 2015
53. Single center experience with hypothermia in acute liver failure. Franco E, **Alsina A**. et.al. ASTS Winter 2016
54. Diagnostic accuracy of MRCP vs. ERCP findings in the post-orthotopic liver transplant population. Shiani A, Wolk B, Lipka S, Pinkas H, Kumar A, **Alsina A**, Kemmer N, Turner A, Brady P. DDW 2016.
55. A tissue-based study of VEGFR2 in human placenta: Association of mitochondrial enzymes pyruvate dehydrogenase component E2 (DLAT) and Sirtuin-4 (SIRT 4). Sinkey R, Okuka M, Stevens S, Steffensen T, Whiteman V, **Alsina A**, and Tsibris J. USF Research Day 2016.
56. Time on waiting list is a poor predictor of recurrence for hepatocellular carcinoma following liver transplantation: A Region 3 single study. **Alsina A**, Makris A, Lahoti M, Nakshabandi A, Parkinson E, Franco S, Albers C, Kemmer N. ASTS Winter 2016.
57. A failure of the past is not a determinant of future outcomes: Report of operations performed by liver transplant surgeons in patients with underlying cirrhosis. **Alsina A**, Athienitis A, et al. AASLD 2016. Presidential Poster of Distinction Award.
58. Utility of MELD –XI in congestive hepatopathy. Kemmer N, **Alsina A**, et al. AASLD 2016.

59. NAFLD in kidney transplant candidates. Kemmer N, **Alsina A**, et al. AASLD 2016.
60. Long term outcomes of hepatitis C liver transplantation in the direct acting antiviral era. **Alsina A**, Athienitis A, et al. AASLD 2017.
61. Hepatocellular carcinoma and hepatitis C transplants outperform other populations in the direct acting antiviral era. **Alsina A**, Athienitis A, et al. Southeastern Surgical Congress, Tampa, FL. (2811312)
62. Is liver transplantation for acute liver failure the nemesis of transplantation? A two-decade psycho-social and long-term outcomes study. **Alsina A**, Athienitis A, et al. Southeastern Surgical Congress, Tampa, FL. (2812392)
63. A two-decade long term outcomes study of liver transplantation: Impact of specialized programs. **Alsina A**, Athienitis A, et al. Southeastern Surgical Congress, Tampa, FL. (2816493)
64. Hepatocellular carcinoma and hepatitis C transplants outperform other populations in the direct acting antiviral era. **Alsina A**, Athienitis A, et al. USF Research Day 2018.
65. Is liver transplantation for acute liver failure the nemesis of transplantation? A two-decade psycho-social and long-term outcomes study. **Alsina AE**, **Alsina AA**, Athienitis A, et al. USF Research Day 2018
66. Is liver transplantation for acute liver failure the nemesis of transplantation? A two-decade psycho-social and long-term outcomes study. **Alsina AE**, **Alsina AA**, Athienitis A, et al. USF Undergraduate Research Colloquium 2018
67. A two-decade long term outcomes study of liver transplantation: Impact of specialized programs. **Alsina A**, Athienitis A, et al. USF Research Day 2018.

### **Abstracts - International**

1. The Impact of Heart Donor and Recipient Cytomegalovirus Status on the Incidence of CMV Infection. Savaria D, Townsend M, Alleman K, **Alsina A**, Olson N, Bartus S, Hull D, and Schweizer R, NATCO Annual Meeting, October 1990, Halifax, Nova Scotia.
2. Orthotopic Porcine Small Bowel Transplantation Using Low Dose Cyclosporine in Triple Immunosuppressive Therapy. **Alsina A**, Nagashima I, and Schweizer R. International Symposium in Small Bowel Transplantation, October 1991, London, Ontario
3. Liver Transplantation in a minority Hispanic population. Torres E, **Alsina A**, et al. Asoc. Latinoamericana Enfermedades de Hígado (ALEH), Margarita Island, Venezuela, July 2008
4. Induced Hypothermia May Improve Outcomes in Patients with High-Grade Encephalopathy Due to Fulminant Hepatic Failure. Franco E, **Alsina A**, et al. World Transplant Congress 2008.
5. Induced Hypothermia in high grade hepatic encephalopathy, The Florida Experience. Behrouz R, Hand HT, Malek AR, **Alsina AE**, Agazzi, Sloan A, van Loveren H, Rumbak M. Temperature Management Congress, Barcelona, Spain. 2008
6. Everolimus safety profile in liver transplant recipients with a 3-year exposure in the H2304 Core and Extension Study. Saliba F, Rogiers X, Chapman W, Caicedo L, **Alsina A**, Teperman, Junge G, Rauer B, Dong G, DeSimone. ILTS 2014

7. The long-term safety with everolimus based regimen in de novo liver transplant recipients: A 4-year results from the Extension of H2304 study. Saliba F, Rogiers X, Chapman W, Caicedo L, **Alsina A**, Teperman, Junge G, Rauer B, Dong G, DeSimone. WTC 2014.
8. Red cell distribution width prior to liver transplantation is associated with post-transplant mortality. Caire T, Kumar A, Stravitz T, Franco E, **Alsina A**, Kemmer N. ILTS 2015
9. Red cell distribution width prior to liver transplantation is associated with post-transplant mortality. Caire T, Kumar A, Stravitz T, Franco E, **Alsina A**, Kemmer N. ILTS 2015